Morgan Stanley Upgrades bluebird bio to Equal-Weight, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has upgraded bluebird bio (NASDAQ:BLUE) from Underweight to Equal-Weight and increased the price target from $3 to $7.
December 08, 2023 | 11:24 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley upgraded bluebird bio's stock rating to Equal-Weight and raised its price target to $7, indicating a more favorable outlook.
Upgrades by prominent analysts like those from Morgan Stanley can lead to increased investor confidence and a potential short-term rise in the stock price. The substantial increase in the price target from $3 to $7 suggests a more optimistic view of the company's prospects, which could attract more buyers to the stock.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100